desloratadine - trima syrup 0.5 mgml
trima israel pharmaceutical products maabarot ltd - desloratadine - syrup - desloratadine 0.5 mg/ml - desloratadine - for the relief of symptoms associated with allergic rhinitis and/or chronic idiopathic urticaria in adults and children 1 year of age and above.
clarinex-d 12 hour- desloratadine and pseudoephedrine sulfate tablet, extended release
physicians total care, inc. - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r), pseudoephedrine sulfate (unii: y9dl7qpe6b) (pseudoephedrine - unii:7cuc9ddi9f) - desloratadine 2.5 mg - clarinex-d® 12 hour extended release tablets is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. clarinex-d 12 hour extended release tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties of pseudoephedrine are desired [see clinical pharmacology (12)] . clarinex-d 12 hour extended release tablets are contraindicated in: - patients with hypersensitivity to any of its ingredients, or to loratadine [see warnings and precautions (5.4) and post-marketing experience (6.2)] - patients with narrow angle glaucoma - patients with urinary retention - patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment [see drug interactions (7.1)] . - patients with severe hypertension or severe coronary artery disease pregnancy category c: there are no adequate and well-controlled stu
clarinex-d 12 hour- desloratadine and pseudoephedrine sulfate tablet, extended release
merck sharp & dohme corp. - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r), pseudoephedrine sulfate (unii: y9dl7qpe6b) (pseudoephedrine - unii:7cuc9ddi9f) - desloratadine 2.5 mg - clarinex-d® 12 hour extended release tablets is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. clarinex-d 12 hour extended release tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties of pseudoephedrine are desired [see clinical pharmacology (12)]. clarinex-d 12 hour extended release tablets are contraindicated in: - patients with hypersensitivity to any of its ingredients, or to loratadine [see warnings and precautions (5.4) and adverse reactions (6.2)] - patients with narrow-angle glaucoma - patients with urinary retention - patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment [see drug interactions (7.1)] - patients with severe hypertension or severe coronary artery disease risk summary the limited available data with clarinex-d 12 hour in pregnant wom
desloratadine 0.5mg/ml oral solution
rosemont pharmaceuticals ltd - desloratadine - oral solution - 0.5mg/ml - antihistamines – h1 antagonist - it is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with: - allergic rhinitis - urticaria
desloratadine 5mg tablets
consilient health ltd - desloratadine - tablet - 5mg
desloratadine 5mg tablets
actavis uk ltd - desloratadine - tablet - 5mg
desloratadine 5mg tablets
aspire pharma ltd - desloratadine - tablet - 5mg
desloratadine 5mg tablets
lupin healthcare (uk - desloratadine - tablet - 5mg
desloratadine 2.5mg5ml oral solution sugar free
rosemont pharmaceuticals ltd - desloratadine - oral solution - 500microgram/1ml
desloratadine 5mg tablets
mylan - desloratadine - tablet - 5mg